Drug Profile
ASP 3026
Alternative Names: ASP-3026Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Astellas Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued B-cell lymphoma; Solid tumours
Most Recent Events
- 31 Mar 2016 Astellas Pharma completes a phase I trial for Solid tumours & B-cell lymphoma in USA (NCT01284192)
- 03 Feb 2014 Discontinued - Phase-I for B-cell lymphoma in USA (PO)
- 03 Feb 2014 Discontinued - Phase-I for Solid tumours in Japan (PO)